Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
03 March 2025 | Story Andre Damons and Adele Louw | Photo Tania Allen
Agriculture Risk Financing research chair
Prof Johan van Niekerk, Vice-Dean for Agriculture for the Faculty of Natural and Agricultural Sciences; Prof Liezel Massyn, UFS Business School; Prof Nicolene Barkhuizen, Director of the UFS Business School; and Prof Cobus Oberholster, from the Agriculture Risk Financing research chair.

A newly established multi-stakeholder research chair at the University of the Free State (UFS) Business School will focus on holistic and interdisciplinary research that will create new knowledge, contribute to climate change adaptation and mitigation in the food and agricultural sector.

The Agriculture Risk Financing research chair, led by Prof Cobus Oberholster from the Business School, will also support sector specific policy development and implementation, and steer the societal discourse on climate financing and sustainable agriculture. The chair forms part of the UFS, Agricultural Research Council (ARC), and the Department of Agriculture, Land Reform and Rural Development (DALRRD) research chairs. Prof Oberholster joined the university on 1 February 2025 in this prestigious position which is a collaboration between the Business School and the UFS Department of Agricultural Economics.

Prof Oberholster, who spent a big portion of his corporate career in the banking environment, brings extensive expertise in climate finance, resource mobilisation, and sustainable economic practices. His appointment marks a significant milestone in advancing research at the intersection of finance, sustainability, and agriculture, ensuring that innovative financial solutions contribute to environmental resilience and responsible resource management. Prof Oberholster also gained extensive management experience over the past 15 years regarding the agribusiness environment (non-Bank) in South Africa with a specific focus on value-chain financing.

Focus of research chair

Says Prof Oberholster: “The research chair will strategically focus on the mainstreaming of climate-smart financing solutions within the food and agricultural sector. To achieve this, the research will focus on three strategic and interrelated pillars (Regulatory and policy, Entrepreneurial market exchanges and Digital financial innovations), which aim to provide a governance framework within which innovative financing and market mechanisms can be developed and commercialised.

“The chair will reside at the UFS Business School, but form part of a group of research chairs being hosted within the Faculty of Natural and Agricultural Science. These chairs cover the full food and agricultural value chain, which allow for leveraging the output of the chair within very specific components of the value agrifood value chain.”

The ARC-DALLRD-UFS research chairs were established last year in an effort to address the challenges and impact of climate change in Southern Africa and fall under the umbrella of climate change.

Prof Oberholster, who completed two doctoral degrees focusing on agriculture, agricultural development, and agricultural financing, says he is excited to be part of this joint initiative, and the opportunity to share his business and financing experience. “Climate change, and the corresponding need to find innovative financing solutions, is currently one of the biggest global challenges. It requires an accelerated and responsible approach to research and innovation which, together with the university’s trusted reputation, must be used to build social licence for disruptive technological solutions.”

Contributing to food security

According to Prof Oberholster, both the UFS Business School and the faculty, are ideally suited to find complementary commercial solutions for accessing and mobilising climate finance in South Africa and the wider African continent. The chair, through the UFS Business School, will also focus on capacity building which will be done through selected training and educational interventions, with the aim of addressing existing constraints in mobilising and accessing climate finance.

“The chair will focus on the integration of social, ethical and environmental parameters into climate-financing decisions. By focusing on these key sustainability aspects, access to climate finance will not only contribute to specific development objectives but also significantly contribute to food security,” Prof Oberholster says.

“Climate change, and the corresponding need to find innovative financing solutions, is currently one of the biggest global challenges. As such I’m looking forward to guide the creation of new knowledge in this specialised field, and especially to find complementary commercial solutions for accessing and mobilising climate finance in South Africa and the bigger African continent. What is standing out for me is the level of expertise available within the UFS, and the willingness of academics to work together on grand challenges such as climate finance. This is a winning recipe.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept